Investors / United States / Casdin Capital
Casdin Capital
Venture capital · New York, NY, United States · North America
Casdin Capital is an investment firm focused on the life sciences, spanning healthcare, biotechnology, synthetic biology, and technology. It partners with companies and builds positions in them to create value.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcarebiotechnologysynthetic biologygenomicsdiagnostics
Your fit with Casdin Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCasdin Capital lists 110 checked portfolio companies on its own site and is named in 16 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 38% of the companies with a known first round. Its largest themes are Healthcare & Biotech (83%), AI & Machine Learning (7%) and Industrial & Manufacturing (3%). 84% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, Andreessen Horowitz and Foresite Capital.
Counts come from funding rounds that name Casdin Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Casdin Capital's whole history. Rounds on record name 16 companies; its own site lists 110. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundCasdin Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 38% |
| Series B | 38% |
| Growth | 25% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 1 | 0 |
| '21 | 2 | 0 |
| '22 | 2 | 0 |
| '23 | 1 | 0 |
| '24 | 1 | 0 |
| '25 | 3 | 0 |
| '26 | 6 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 96th | 110 companies |
| Recent activity | 89th | 6 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 77th | 10% of companies confirmed by a round |
| Sector focus | 94th | 83% in its largest sector |
| Reach | 93th | 9 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 83% | 15% |
| AI & Machine Learning | 7% | 18% |
| Industrial & Manufacturing | 3% | 7% |
| Education | 3% | 7% |
| Media & Entertainment | 1% | 4% |
| Consumer | 1% | 3% |
| Food & Agriculture | 1% | 3% |
| Fintech | 1% | 12% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 14 |
| Andreessen Horowitz | 13 |
| Foresite Capital | 11 |
| Nextech Invest | 11 |
| RA Capital | 10 |
| SoftBank Vision Fund | 9 |
| Catalio Capital Management | 8 |
| GV | 8 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers10495%
- No longer answers00%
- Points to another company65%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Casdin Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Casdin Capital| Date | Company | Stage |
|---|---|---|
| 6 Oct 2026 | Series B | |
| 30 Jun 2026 | Series C+ | |
| 23 Jun 2026 | Series A | |
| 8 Jun 2026 | Series B | |
| 8 Jan 2026 | Series B | |
| 13 Nov 2025 | Series B | |
| 4 Sept 2025 | Series C+ | |
| 3 Sept 2025 | Series A |
Round details for Casdin Capital
Amounts, full round histories and every co-investor in Casdin Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
110 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 23andMe sells DNA testing kits and subscription plans that report on a person's genetic ancestry and genetic health risks. | Healthcare & BiotechConsumer | Portfolio page | ||
| The company invents and develops genetic medicines with proprietary customized vectors for retinal and pulmonary diseases. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| A2 Biotherapeutics is advancing a cell engineering platform to create precision CAR T-cell therapies for cancer and other diseases. | Healthcare & Biotech | Portfolio page | ||
| Absci creates biologics with AI technology | Healthcare & Biotech | Portfolio page | ||
| Adaptive Biotechnologies harnesses the adaptive immune system to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine | Healthcare & Biotech | Portfolio page | ||
| Affinia Therapeutics develops gene therapies, specifically adeno-associated virus (AAV) gene therapy, for diseases such as BAG3-associated dilated cardiomyopathy | Healthcare & Biotech | Portfolio page | ||
| Alector develops therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Aledade provides actionable insights and expert support for clinicians to keep their patients healthy while generating sustainable revenue through its accountable care organizations (ACOs). | Healthcare & Biotech | Portfolio page | ||
| AmplifyBio provides services for drug discovery, characterization, and optimization, including preclinical CRO and CDMO services | Healthcare & Biotech | Portfolio page | ||
| Amplo develops gene therapies for diseases of the neuromuscular junction | Healthcare & Biotech | Portfolio page | ||
| Apella provides ambient AI for operating rooms to optimize capacity, streamline coordination, and improve patient care. | Healthcare & BiotechAI & Machine Learning | Jan 2026Series B | Page + round | |
| Arzeda designs proteins for various applications, including sweeteners, home care, advanced materials, and biologics. | Healthcare & BiotechFood & Agriculture | Portfolio page | ||
| Asimov designs and manufactures genetic systems and therapies using synthetic biology and computational tools. | Healthcare & Biotech | Portfolio page | ||
| Auron Therapeutics targets cell state plasticity to improve patient outcomes in oncology and inflammatory disease | Healthcare & Biotech | Portfolio page | ||
| Beacon Biosignals uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| Blueprint turns ideas into wiring diagrams, parts lists, and purchase information | AI & Machine LearningIndustrial & Manufacturing | Portfolio page | ||
| Boundless Bio develops therapies for patients with intractable oncogene amplified cancers. | Healthcare & Biotech | Jun 2026Series A | Funding round | |
| Burning Rock Dx is a global diagnostics company focusing on applying next-generation sequencing technology in precision oncology. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page |
About this data
site last read 10 Nov 2026- Site
- casdincapital.com
- Last read
- 10 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 26 May 2020
- Companies checked
- 110
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Casdin Capital's profile as data
Pull Casdin Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/casdincapital.com
# also
GET /v1/firms/casdincapital.com/portfolio
GET /v1/firms/casdincapital.com/coinvestors
GET /v1/firms/casdincapital.com/news